SDIC Gaoxin, Takeda Pharmaceuticals deal published by China's SAMR for simple case review
MLex Summary: The proposed acquisition by China SDIC Gaoxin Industrial Investment of Takeda Pharmaceuticals International’s business related to cardiovascular and metabolic drugs has been published for a simple case review by...To view the full article, register now.
Already a subscriber? Click here to view full article